Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.39 |
| ▸ | CASR | P41180 | 4/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20320415 | 0.80 | NOTUM (0.55) | KCNH2NOTUM | |
| SCHEMBL16202024 | 0.79 | MAPK10 (0.42) | NOTUMMAPK10 | |
| SCHEMBL13183810 | 0.79 | ALDH1A1 (0.45) | NOTUMMAPK10CYP11B2ADORA3 | |
| SCHEMBL18284894 | 0.79 | DHFR (0.42) | KCNH2NOTUMTDP1CASRBRAF | |
| SCHEMBL16030261 | 0.79 | NOTUM (0.41) | KCNH2NOTUMTDP1CASRBRAF | |
| SCHEMBL10360310 | 0.79 | NOTUM (0.44) | KCNH2NOTUMTDP1CASRBRAF | |
| SCHEMBL14617482 | 0.78 | POLB (0.46) | MAPK10PTGS2 | |
| SCHEMBL31348082 | 0.78 | MAPT (0.47) | TDP1 | |
| SCHEMBL22184942 | 0.78 | CASR (0.42) | KCNH2NOTUMTDP1CASRBRAF | |
| SCHEMBL17380732 | 0.78 | MAPT (0.39) | KCNH2BRAFSRCKDRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | disclosed |
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| WO-2018114596-A1 | SUBSTITUTED HETEROARYL PYRROLONES AND SALTS THEREOF AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| US-9271501-B2 | Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors | BASF SE (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | DDT, NOTUM, AGPS | KCNH2 1508/4885NOTUM 2/4885TDP1 2854/4885 |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | KCNH2 1781/4885NOTUM 3419/4885TDP1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.